The role of diffusion tensor imaging for the assessment of liver fibrosis and inflammation in chronic viral hepatitis: A preliminary study

Year 2020, Volume: 33 Issue: 2, 97 - 101, 31.05.2020

Ozge Yapıcı Ugurlar Mehmet Sait Bugdaycı Abdullah Soydan Mahmutoglu Canan Alkım Banu Yılmaz Ozguven Alper Ozel Muzaffer Basak Yasin Aykut Huseyin Ozkurt Sukru Mehmet Erturk

https://doi.org/10.5472/marumj.741724

Abstract

Objective: To evaluate the role of magnetic resonance (MR) diffusion tensor imaging (DTI) in the assessment of liver fibrosis and
inflammation in chronic viral hepatitis by measuring apparent diffusion coefficient (ADC) and fractional anisotropy (Fa) values.
Material and Methods: Twenty-seven patients (5 women and 22 men;mean age39.8±11.3) with hepatic fibrosis were included in
our study. The relationship between ADC, Fa values and histological activity index (HAI) score were evaluated using Spearman’s
correlation coefficient. Patients were subgrouped as group A (fibrosis score 1) and group B (fibrosis score 3). The mean ADC and Fa
values of groups A and B were compared using Student’s t-test. To evaluate the use of ADC and Fa values in distinguishing group A
from group B, ROC analysis was applied; sensitivities and specificities were calculated.
Results: Fa values correlated with HAI scores significantly (r=0.397, p<0.05) The difference was significant between the mean ADC
values (group A:1.46± 0.191x103mm2/s; group B:1.105± 0.141x10-3 mm2/s; p<0.001) and Fa values (group A: 0.473±0.091; group
B: 0.643± 0.007; p<0.001) between the groups. For distinguishing group A from group B, ADC had a sensitivity of 81.8% and a
specificity of 93.8%. The sensitivity and specificity of Fa were 90.9% and 100%, respectively.
Conclusion: Diffusion tensor imaging may play a role in the evaluation of fibrosis and HAI scores in patients with liver fibrosis.

Keywords

Hepatitis, Liver fibrosis, Diffusion tensor imaging

References

• [1] Taouli B, Chouli M, Martin AJ, et al. Chronic hepatitis: role of diffusion weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008; 28:89-95. doi.org/10.1002/jmri.21227.
• [2] Annet L, Peeters F, Abarca-Quinones J, Leclercq I, Moulin P, Van Beers BE. Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging 2007; 25:122-8. doi:10.1002/jmri.20771.
• [3] Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006;239:425-37. doi.org/10.1148/radiol. 239.205.0505.
• [4] Bonekamp S, Torbenson MS, Kamel IR. Diffusion-weighted magnetic resonance ımaging for the staging of liver fibrosis. J Clin Gastroenterol 2011;45:885-92. doi: 10.1097/ MCG.0b013e318223bd2c.
• [5] Sandrasegaran K, Fatih M, Akisik FM, et al. Value of diffusionweighted MRI for assessing liver fibrosis and cirrhosis. Am J Roentgenol 2009;193:1556-60. doi:10.2214/AJR.09.2436
• [6] Koinuma MN, Ohashi I, Hanafusa K, et al. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005;22:80-5.doi. org/10.1002/jmri.20344.
• [7] 7. Taouli B, Toila AJ, Losada M, et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. Am J Roentgenol 2007;189:799-806. doi:10.2214/AJR.07.2086.
• [8] 8. Girometti R, Furlan A, Bazzocchi M, etal. Diffusionweighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med 2007;112:394-408. doi: 10.1007/ s11547.007.0149-1.
• [9] Soylu A, Kılıçkesmez Ö, Poturoğlu Ş, et.al. Utility of diffusionweighted MRI for assessing liver fibrosis in patients with chronic active hepatitis. Diagn Interv Radiol 2010; 16:204-8. doi: 10.4261/1305-3825.DIR. 2810-09.1. [10] Bakan AA, Inci E, Bakan S, Gokturk S, Cimilli T. Utility of diffusion-weighted imaging in the evaluation of liver fibrosis. EurRadiol 2012;22: 682-7. doi:10.1007/s00330.011.2295-z.
• [11] Taouli B, Martin AJ, Qayyum A, Merriman RB, et.al. Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: Preliminary experience in healthy volunteers. AJR Am J Roentgenol 2004;183:677-80. doi: 10.2214/ ajr.183.3.1830677.
• [12] Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5. doi.org/ 10.1002/hep.184.001.0511.
• [13] Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36:47-56. doi: 10.1053/jhep.2002.36993.
• [14] Davis JA. Elementary survey analysis. Englewood Cliffs, NJ: Prentice-Hall,1971:49.
• [15] Shiffman ML, Benhamou Y. Patients with HCV and F1 and F2 fibrosis stage:treat now or wait? Liver Int 2013; 33:105-10. doi: 10.1111/liv.12066.
• [16] Tosun M, Inan N, Sarisoy HT, et.al. Diagnostic performance of conventional diffusion weighted imaging and diffusion tensor imaging for the liver fibrosis and inflammation. Eur J Radiol. 2013;82(2):203-7. doi: 10.1016/j.ejrad.2012.09.009.